Anthropic launched its drug discovery program today. It’s a clear move into neglected-disease research, and it also introduces Claude Science, the company’s workbench for genomics, proteomics, and single-cell analysis.
The company is moving past selling tools to labs and into preclinical discovery itself. Anthropic’s argument is that this stage fits AI unusually well: biology data is abundant, simulation and ranking can happen quickly, and failures cost less here than they do later in the process. If that plays out, early medicine development could speed up, and the work could feed back into better life-sciences products.
There’s a different business model here too. Anthropic says its public benefit corporation structure gives it room to put patients’ needs ahead of short-term returns. That comes at a moment when Novartis CEO Vas Narasimhan has said these tools could cut timelines from about 12 years to 7 or 8, while pushing success rates from roughly 8% to 16%. Anthropic also says Claude Science connects to more than 60 databases. In its early examples, a University of California, San Francisco researcher spotted viral contamination in minutes after it had been missed for a year, and another analysis covered 100 rare genetic diseases in under an hour and surfaced 32 follow-up candidates.
If you follow AI in biotech, this deserves a close look. Discovery is still only the first part. Clinical trials cost come after that.
You can get Claude Science through Anthropic’s research offering, and Anthropic’s new drug program is starting with preclinical work.
Author: Anthony John Padilla
{
"social": {
"email": "content.reviewer90@ext.softonic.com",
"facebook": "",
"twitter": "",
"linkedin": "https:\/\/www.linkedin.com\/in\/anthony-padilla-330a04299\/"
},
"ja-JP": "",
"de-DE": "Anthony Padilla ist ein auf den Philippinen ansässiger Schriftsteller mit Erfahrung in redaktionellen, digitalen und markenorientierten Inhalten. Seine Arbeit konzentriert sich darauf, komplexe Ideen in klare, verständliche Texte umzuwandeln.",
"en-US": "Anthony Padilla is a Philippines-based writer with experience across editorial, digital, and brand-focused content. His work centers on translating complex ideas into clear, accessible copy, with a strong emphasis on structure, accuracy, and user-focused communication. He has contributed to long-form articles, product and platform copy, and marketing-led editorial pieces.",
"es-ES": "Anthony Padilla es un escritor con base en Filipinas con experiencia en contenido editorial, digital y enfocado en marca. Su trabajo se centra en traducir ideas complejas en textos claros y accesibles.",
"fr-FR": "Anthony Padilla est un écrivain basé aux Philippines ayant de l'expérience dans le contenu éditorial, numérique et axé sur la marque. Son travail consiste à traduire des idées complexes en textes clairs et accessibles.",
"it-IT": "Anthony Padilla è uno scrittore con base nelle Filippine con esperienza in contenuti editoriali, digitali e focalizzati sul brand. Il suo lavoro si concentra sulla traduzione di idee complesse in testi chiari e accessibili.",
"nl-NL": "Anthony Padilla is een schrijver gevestigd op de Filipijnen met ervaring in redactionele, digitale en merkgerichte content. Zijn werk richt zich op het vertalen van complexe ideeën naar helder, begrijpelijke teksten.",
"pl-PL": "Anthony Padilla to pisarz mieszkający na Filipinach z doświadczeniem w tworzeniu treści redakcyjnych, cyfrowych i skoncentrowanych na marce. Jego prace skupiają się na przekształcaniu skomplikowanych idei w jasne, zrozumiałe teksty.",
"pt-BR": "Anthony Padilla é um escritor baseado nas Filipinas com experiência em conteúdo editorial, digital e focado em marca. Seu trabalho se concentra em traduzir ideias complexas em textos claros e acessíveis."
}
View all posts by Anthony John Padilla
